SCHEMBL3250293

SCHEMBL3250293

Cc1nc(NS(=O)(=O)c2cccc(Cl)c2C)sc1CC(=O)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 10/20 0.60
HSD17B1 P14061 2/20 0.58
HSD17B2 P37059 2/20 0.58
HTT P42858 1/20 0.45
KDM4E B2RXH2 1/20 0.44
P2RX7 Q99572 1/20 0.43
EDNRB P24530 2/20 0.42
EDNRA P25101 2/20 0.42
HTR2C P28335 1/20 0.41
CCKBR P32239 1/20 0.39
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617537 0.87 HSD11B1 (0.60) HSD11B1HSD17B1HSD17B2HTTKDM4E
SCHEMBL5830983 0.84 HSD11B1 (0.61) HSD11B1HSD17B1HSD17B2KDM4EP2RX7
SCHEMBL3255959 0.84 HSD11B1 (0.83) HSD11B1HSD17B1HSD17B2KDM4EP2RX7
SCHEMBL5831502 0.84 HSD11B1 (0.58) HSD11B1HSD17B1HSD17B2KDM4EP2RX7
SCHEMBL3615493 0.84 HSD11B1 (0.82) HSD11B1HSD17B1HSD17B2KDM4EP2RX7
SCHEMBL3258438 0.82 HSD11B1 (0.53) HSD11B1HSD17B1HSD17B2HTTKDM4E
SCHEMBL3251122 0.82 HSD11B1 (0.67) HSD11B1HSD17B1HSD17B2KDM4E
SCHEMBL6623953 0.81 HSD11B1 (0.55) HSD11B1HSD17B1HSD17B2KDM4EP2RX7
SCHEMBL6454781 0.80 HSD11B1 (0.82) HSD11B1HSD17B1HSD17B2KDM4EP2RX7
SCHEMBL6624322 0.80 HSD11B1 (0.55) HSD11B1HSD17B1HSD17B2KDM4EP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US disclosed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.